Xspray Pharma: Slightly raised fair value range following XS003 results and CMD - Redeye

Redeye returns with a slightly upwards adjusted valuation following the XS003 data and capital markets day. The company has reported a tangible step forward with XS003, and the current timeline opens up for a potential NDA filing by H2 2024. The CMD provided further insights into both the Dasynoc FDA approval process and the anticipated Q3 2024 launch, among other things.

Länk till analysen i sin helhet: https://www.redeye.se/research/962890/xspray-pharma-slightly-raised-fair-value-range-following-xs003-results-and-cmd?utm_source=finwire&utm_medium=RSS